Kathryn E. Hall

Kathryn E. Hall

Auto-generated profile, based on publicly available information

Kathryn E. Hall

Translational and Clinical Research Centers Massachusetts General Hospital Boston Massachusetts USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2020 in medRxiv
Verified
Preprint
Open access
PDF file
JFJesse M Fajnzylber
Jesse M Fajnzylber
JRJames Regan
James Regan
KCKendyll Coxen
Kendyll Coxen
HCHeather Corry
Heather Corry
CWColline Wong
Colline Wong
JLJonathan Z. Li
Jonathan Z. Li
The relationship between SARS-CoV-2 viral load and risk of disease progression remains largely undefined in coronavirus disease 2019 (COVID-19). We quantified SARS-CoV-2 viral load from participants with a diverse range of COVID-19 severity, including those requiring hospitalization, outpatients with mild disease, and individuals with resolved infection. SARS-CoV-2 plasma RNA was detected in 27% of hospitalized participants and 13% of outpatients diagnosed with COVID-19. Amongst the participants hospitalized with COVID-19, higher prevalence of detectable SARS-CoV-2 plasma viral load was associated with worse respiratory disease severity, lower absolute lymphocyte counts, and increased markers of inflammation, including C-reactive protein and IL-6. SARS-CoV-2 viral loads, especially plasma viremia, were associated with increased risk of mortality. SARS-CoV-2 viral load may aid in the risk stratification of patients with COVID-19 and its role in disease pathogenesis should be further explored.

1 March 2025 in Neurology Education
Verified
Journal Article
Open access
KSKathryn Swider
Kathryn Swider
CCCalli Cook
Calli Cook
JDJustin DiLibero
Justin DiLibero
KHKathryn E. Hall
Kathryn E. Hall
MNMargaret Naclerio
Margaret Naclerio
DHDaniel Harrison
Daniel Harrison
A growing number of nurse practitioners (NPs) are entering neurologic practice. Postgraduate educational needs of NPs are partly dictated by previous neurologic educational experience, which is not well defined. We aim to describe neurologic education in NP programs to better inform efforts to develop tailored educational initiatives. A website review was performed to identify accredited NP programs and program leaders. A previously developed survey designed to facilitate a description of neurologic education in physician assistant (PA) programs was adapted for NP program leaders by an iterative approach. The survey was distributed in spring and fall 2023. Three hundred and thirty-three Family NP, 140 Adult-Gerontologic Primary Care NP, and 136 Adult-Gerontologic Acute Care NP registered programs were identified. Leaders of 206 programs completed the survey (response rate = 34.9%). Two hundred four respondents (99.0%) reported neuroscience didactics included within their curriculum, typically contained within core, discipline-based courses. Neurologic disease and examination (n = 201, 98%) were covered most while lesion localization (n = 37, 18.0%) and neuroradiology (n = 50, 24.3%) were taught least often. Of 201 respondents who indicated that neurologic examination is included, 175 (87.1%) reported a hands-on approach. Didactic neuroscience instructors were specialized in clinical neurology in 109 programs (53.4%). One hundred sixty-nine programs (82.0%) offer a neurology clinical rotation, typically as an elective. Of respondents who provided an estimate, most reported that 10% or fewer of their students complete a neurology clinical rotation per year (n = 62, 77.5%). The most frequently reported barrier to offering clinical placement in neurology was lack of neurology preceptors (n = 85, 56.6%). Programs reporting graduates pursuing careers in neurology were associated with larger size, acute care track, and neurology NP as a didactic neuroscience instructor. Lesion localization and neuroradiology are important targets for postgraduate training of NPs entering neurologic practice. Recruiting neurology NPs to teach neuroscience didactics may increase programs with students pursuing careers in neurology. Availability of clinical neurology rotations is not universal in NP programs. Encouraging neurology clinicians, including PAs and physicians, to precept NP students could help increase access to clinical neurology rotations. These results highlight important opportunities for augmenting neurologic education during and after NP programs.

1 June 2025 in Neurology Education
Verified
Journal Article
Closed access
KSKathryn Swider
Kathryn Swider
CCCalli Cook
Calli Cook
JDJustin DiLibero
Justin DiLibero
KHKathryn E. Hall
Kathryn E. Hall
MNMargaret Naclerio
Margaret Naclerio
DHDaniel Harrison
Daniel Harrison
[This corrects the article DOI: 10.1212/NE9.0000000000200190.].

12 June 2026 in Muscle & Nerve
Verified
Journal Article
Open access
AWAlison Wheeler
Alison Wheeler
KMKush Mehta
Kush Mehta
DSDanica Sanders
Danica Sanders
CCCathy Chin
Cathy Chin
HZHannah Zivalic
Hannah Zivalic
SBSuma Babu
Suma Babu
Introduction/Aims: Tofersen is a gene‐targeted therapy for individuals with superoxide dismutase 1 ( SOD1 ) (+) amyotrophic lateral sclerosis (ALS). Prior to U.S. Food and Drug Administration (FDA) approval, tofersen was made available through expanded access protocol. This study describes the clinical and operational experience of administering tofersen through expanded access protocols at a single academic medical center in the U.S. Methods: Individuals with symptomatic SOD1 (+) ALS (≥ 18 years), who were ineligible for traditional ALS clinical trials, received tofersen via bedside lumbar punctures at Massachusetts General Hospital. Treatment was provided through single‐patient and intermediate‐sized expanded access protocols prior to FDA approval. Demographic and clinical characteristics, referral‐to‐treatment timelines, safety outcomes, and operational costs were collected. Results: Eleven individuals with SOD1 (+) ALS received monthly intrathecal tofersen over a two‐year period (July 2021 to July 2023). Most participants were female, and 81.8% had leg‐onset ALS. The mean (SD) referral‐to‐first dose duration was 36 (22.4) days. A total of 120 doses were administered over a two‐year period. Tofersen was safe and well tolerated, with no treatment‐related serious adverse events. Operational costs totaled $336,620, supported by philanthropy and insurance. The company provided the drug for free. Discussion: This experience demonstrates the feasibility of implementing a resource‐intensive expanded access protocol within an academic medical center using a mixed funding model to facilitate early access to emerging ALS therapies.